1. Home
  2. GO vs OMER Comparison

GO vs OMER Comparison

Compare GO & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grocery Outlet Holding Corp.

GO

Grocery Outlet Holding Corp.

HOLD

Current Price

$5.93

Market Cap

960.8M

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$11.23

Market Cap

821.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GO
OMER
Founded
1946
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
960.8M
821.7M
IPO Year
2019
2008

Fundamental Metrics

Financial Performance
Metric
GO
OMER
Price
$5.93
$11.23
Analyst Decision
Hold
Strong Buy
Analyst Count
10
5
Target Price
$11.30
$32.50
AVG Volume (30 Days)
4.1M
714.8K
Earning Date
06-04-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,688,759,000.00
$29,868,000.00
Revenue This Year
$8.24
N/A
Revenue Next Year
$5.83
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.26
N/A
52 Week Low
$5.66
$2.95
52 Week High
$19.41
$17.65

Technical Indicators

Market Signals
Indicator
GO
OMER
Relative Strength Index (RSI) 24.27 44.69
Support Level $5.66 $11.09
Resistance Level $10.42 $11.90
Average True Range (ATR) 0.44 0.45
MACD -0.23 -0.03
Stochastic Oscillator 5.57 19.64

Price Performance

Historical Comparison
GO
OMER

About GO Grocery Outlet Holding Corp.

Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: